-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $41

Benzinga·10/28/2026 09:55:01
Listen to the news
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $40 to $41.